Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT04304261

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04304261
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04304261. Randomized; no masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2023-12-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
Acronym
ESCDP
Condition
Diabetes Mellitus, Type 2
Condition
Cognitive Functions Confusion
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Sitagliptin
Lead sponsor
Third Military Medical University (class: other)

Record details

Record id
cardio:ct-nct04304261
Content hash
acd4fd820121b95d3af93bbcd0173673b04ff17680ad5adc2b4be0d421e5ddbe